REGENERON PHARMACEUTICALS, INC.REGN

Market cap

$81.6B

P/E ratio

	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Product	-	-	-	-	-	-	-	-	4,106	4,834	5,568	12,117	6,894	7,078	7,629
Collaboration revenue	-	-	-	-	-	-	-	-	-	-	-	1,902	2,058	5,503	6,058
Other revenue	-	-	-	-	-	-	-	-	1,111	1,427	1,186	281	365	536	515
Revenue from contract with customer	-	-	-	-	-	-	-	-	6,711	7,863	8,497	16,072	12,173	13,117	14,202
Research and development	489	530	626	860	1,271	1,621	2,052	2,075	2,186	3,037	2,735	2,908	3,593	4,439	5,132
Acquired in-process research and development	-	-	-	-	-	-	-	-	-	-	-	-	255	186	101
Selling, general, and administrative	65	117	211	329	505	839	1,178	1,320	1,556	1,835	1,346	1,825	2,116	2,631	2,954
Product	-	-	-	-	-	-	-	-	180	362	492	1,773	800	932	1,087
Cost of collaboration and contract manufacturing	-	-	-	-	-	-	-	-	254	420	628	664	760	884	883
Other operating expense (income), net	-	-	-	-	-	-	-	-	-	-	280	46	90	2	-53
Total expenses	557	651	921	1,345	1,981	2,852	3,530	3,793	4,176	5,654	4,921	7,125	7,434	9,070	10,211
Income from operations	-97	-205	458	760	838	1,252	1,331	2,080	2,534	2,210	3,577	8,947	4,739	4,047	3,991
Other income (expense), net	-	-	-	-	-	6	6	24	47	250	291	436	179	225	844
Interest expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55
Total other income (expense)	-7	-18	-43	-47	-63	-27	-1	-1	19	219	234	379	120	152	789
Income before income taxes	-	-	-	-	-	-	-	-	-	-	-	9,326	4,859	4,199	4,780
Income tax expense	-	-1	-336	289	428	589	434	880	109	313	297	1,251	520	246	367
Net income	-104	-222	750	424	348	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Earnings Per Share, Basic	-	-	7.92	4.33	3.46	6.17	8.55	11.27	22.65	19.38	32.65	76.4	40.51	37.05	40.9
Earnings Per Share, Diluted	-	-	6.75	3.81	3.07	5.52	7.7	10.34	21.29	18.46	30.52	71.97	38.22	34.77	38.34
Net income	-104	-222	750	424	348	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Unrealized gain (loss) on debt securities	-	-	1	-0	53	-44	-21	13	-7	36	9	-56	-214	158	74
Loss on foreign currency translation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1
Comprehensive income	-	-	751	424	402	592	874	1,212	2,438	2,149	3,521	8,020	4,126	4,112	4,486